Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript

HHS Public Access

Author manuscript

Curr Drug Targets. Author manuscript; available in PMC 2015 April 23.

Published in final edited form as:

Curr Drug Targets. 2013 July ; 14(8): 919–935.

Hypoxia-Inducible Factor-1 (HIF-1): A Potential Target for Intervention in Ocular Neovascular Diseases

Ramya Krishna Vadlapatla, **Aswani Dutt Vadlapudi**, and **Ashim K. Mitra**[*]

Division of Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, 2464 Charlotte Street, Kansas City, MO 64108-2718, USA

Abstract

Constant oxygen supply is essential for proper tissue development, homeostasis and function of all eukaryotic organisms. Cellular response to reduced oxygen levels is mediated by the transcriptional regulator hypoxia-inducible factor-1 (HIF-1). It is a heterodimeric complex protein consisting of an oxygen dependent subunit (HIF-1α) and a constitutively expressed nuclear subunit (HIF-1β). In normoxic conditions, *de novo* synthesized cytoplasmic HIF-1α is degraded by 26S proteasome. Under hypoxic conditions, HIF-1α is stabilized, binds with HIF-1β and activates transcription of various target genes. These genes play a key role in regulating angiogenesis, cell survival, proliferation, chemotherapy, radiation resistance, invasion, metastasis, genetic instability, immortalization, immune evasion, metabolism and stem cell maintenance. This review highlights the importance of hypoxia signaling in development and progression of various vision threatening pathologies such as diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration and glaucoma. Further, various inhibitors of HIF-1 pathway that may have a viable potential in the treatment of oxygen-dependent ocular diseases are also discussed.

Keywords

Age-related macular degeneration; diabetic retinopathy; hypoxia signaling; hypoxia-inducible factor-1 (HIF-1); ocular neovascularization; retinopathy of prematurity

Hypoxia and the Discovery of HIF-1

A constant oxygen supply is essential for proper tissue development, homeostasis and function of all eukaryotic organisms. Cells require oxygen as an electron acceptor during oxidative phosphorylation for efficient ATP production. Oxidative phosphorylation produces higher energy (∼18 fold) than glycolysis [1, 2]. Oxygen serves as a major element in regulating membrane transport, intracellular signaling, expression of many genes, and cell survival [3, 4]. Hypoxia (∼1% O_2) occurs when tissue oxygenation demand exceeds the vascular supply. Response to reduced oxygen levels is mediated by the transcriptional

© 2013 Bentham Science Publishers

[*]Address correspondence to this author at the University of Missouri Curators' Professor of Pharmacy, Chairman, Pharmaceutical Sciences, Vice-Provost for Interdisciplinary Research, University of Missouri-Kansas City, School of Pharmacy, 2464 Charlotte Street, Kansas City, MO 64108-2718, USA; Tel: 816-235-1615; Fax: 816-235-5779; mitraa@umkc.edu.

Conflict of Interest: The authors confirm that this article content has no conflicts of interest.

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

regulator hypoxia-inducible factor 1 (HIF-1). HIF-1 was first discovered by its ability to induce expression of erythropoietin (EPO) in kidney and liver. Such production of EPO is inversely related to tissue oxygen concentration. In response to hypoxia, EPO is stimulated which in turn promotes red blood cell production and oxygen carrying capacity. This information led to the identification of a hypoxia response element (HRE; 5′-RCGTG-3′) in the 3′-enhancer region of EPO [5, 6].

Structure of HIF-1

A functional HIF-1 system is expressed in all metazoan species including the simplest animal *Trichoplax adhaerens* [7]. The *HIF1A* gene was mapped on 14q21-q24 human chromosome. HIF-1 is a heterodimeric complex consisting of an oxygen dependent subunit (HIF-1α) and a constitutively expressed nuclear subunit (HIF-1β) [8]. HIF-1β is also known as the aryl hydrocarbon receptor nuclear translocator (ARNT). It was first identified as structural binding component of aryl hydrocarbon receptor (AHR), which induces the transcription of Cyp1a1 metabolizing enzyme [9]. Both subunits are members of basic helix-loop-helix-PER-ARNT-SIM (bHLH-PAS) protein family. In human, *HIF1A*, *EPAS1* and *HIF3A* genes encode three different isoforms of HIF-α (HIF-1α, HIF-2α and HIF-3α), respectively [10].

Structurally, HIF-1α exhibits bHLH and PAS domains at the N-terminal. The bHLH domain and N-terminal of PAS (PAS-A) (amino acids/aa 1-166) facilitate DNA dimerization while complete bHLH and PAS domains (aa 1-390) facilitate DNA binding [11, 12]. HIF-1α also exhibits an oxygen-dependent degradation (ODD) domain, two transactivating domains (TADs) and two nuclear localizing signals (NLS). The ODD domain (aa 401-575) located within central region plays a predominant role in regulating stability of HIF-1α with respect to oxygen concentration [13]. Two TADs (N-TAD; aa 531-575 and C-TAD; 786-826) help in recruiting various coactivators required for transcription of target genes. Bridged between them is an inhibitory domain (ID; aa 576-785) capable of repressing their transcriptional activity under normoxic conditions (~20% O_2) [14, 15]. N-NLS (aa 17-30) and C-NLS (aa 718-721) promote nuclear translocation of HIF-1α. However, studies have demonstrated that nuclear import is highly dependent on C-NLS [16]. HIF-1α is ubiquitously expressed in all human tissues, while the other related protein HIF-2α is primarily expressed in lung, endothelium and carotid artery [17-19]. HIF-2α shares 48% structural identity with HIF-1α. A third protein, HIF-3α, is also expressed in many tissues including adult thymus, lung, brain, heart, and kidney. This protein lacks C-TAD. However, the N-terminus of this protein shares 57% and 53% structural homology with HIF-1α and HIF-2α, respectively [20, 21]. A splice variant of HIF-3α is the inhibitory PAS domain (IPAS) protein, primarily expressed in Purkinje cells and corneal epithelium. This variant acts like a negative regulator of HIF-1 by binding to amino terminal region of HIF-1α, preventing transactivation. Further, this protein is also induced under hypoxia in heart and lung, suggesting a negative feedback mechanism for HIF-1 activity [22, 23]. The domain organization of both the subunits (HIF-1α and HIF-1β) is depicted in Fig. 1.

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

Regulation of HIF-1

Functional activity of HIF-1 is regulated by levels of oxygen dependent HIF-1α subunit. Although transcription of HIF-1α mRNA occurs at normoxic conditions, the protein is rapidly degraded *via* the ubiquitin proteasome pathway [24, 25]. HIF-1α protein has a very short half-life ($t_{1/2}$~5 minutes) and its stability is highly regulated by posttranscriptional modifications including hydroxylation, ubiquitination, acetylation, phosphorylation and nitrosation [26, 27].

Prolyl Hydroxylation

Hydroxylation of proline residues led to the identification of oxygen sensing mechanism of HIF-1α [28, 29]. It was considered a major breakthrough in delineating the signal transduction of HIF-1. Mutagenic studies substituting proline stabilized HIF-1α even under normal oxygen tension, demonstrate its importance in regulating transcriptional responses. Two proline residues (Pro/P 402 and 564) located within ODD domain are rapidly hydroxylated by 2-oxoglutarate (2-OG) dependent dioxygenases [30-32]. These dioxygenases recognize a conserved amino acid sequence 'LXXLAP', where X represents any amino acid. Human dioxygenases have been coined as prolyl hydroxylases (PHDs) or HIF- prolyl hydroxylases (HPHs) [33]. PHDs require oxygen for hydroxylation as well as ferrous ion (Fe^{2+}) and ascorbate as cofactors [34]. During hydroxylation an oxygen molecule is split so that one oxygen atom is transferred on to proline while the other reacts with 2-OG to produce succinate and CO_2 [30, 35]. Absolute requirement for Fe^{2+} ion stems from the observation that iron chelators or transition metal ions can suppress hydroxylation either by reducing the availability of Fe^{2+} or substituting Fe^{2+} at the active binding site [36, 37]. Ascorbate plays a very important role in regulating the activity of PHDs and maintaining the Fe^{2+} state of iron [35].

Molecular cloning studies have identified three isoforms of PHDs (PHD 1, 2 and 3) [38]. All the three isoforms can hydroxylate HIF-1α, with the highest activity exhibited by PHD2. The relative *in vitro* hydroxylation activity can be demonstrated as PHD2 $\gg$ PHD3 $>$ PHD1 [33, 39]. Subcellular localization of these isoforms varies. PHD1 is exclusively localized in the nucleus; while PHD2 is localized in the cytoplasm and PHD3 is found in both compartments. However, PHD2 is able to shuttle between cytoplasmic and nuclear components facilitating HIF-1α degradation in both compartments. Further studies have suggested that PHD2 and PHD3 mRNA expression is hypoxia inducible, while PHD1 mRNA expression is not altered by hypoxia [40].

Polyubiquitination

Post hydroxylation, von Hippel-Lindau protein (pVHL) binds HIF-1α. X-ray crystallographic studies have demonstrated that hydroxyproline fits accurately into a pocket in pVHL hydrophobic core and this binding is highly specific [41, 42]. Moreover, pVHL associates with elongin C and this interaction is stabilized by elongin B. Cullin-2 and Rbx1 proteins are also recruited to form the VCB-Cul2 E3 ligase complex which facilitates polyubiquitination and degradation by the 26S proteasome [43, 44]. Although pVHL-E3 ligase complex is predominantly expressed in the cytoplasm, cytoplasmic-nuclear trafficking

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

of the complex facilitates HIF-1α degradation in both compartments [45, 46]. pVHL thus plays a predominant role in the degradation of HIF-1α. Loss of activity or mutation of pVHL has been implicated in the development of many disease processes due to induction of hypoxia regulated genes [47-49].

Lysine Acetylation

Jeong *et al*., have identified a key lysine residue (Lys/K 532) that plays a crucial role in determining proteasomal degradation of HIF-1α. An acetyl group of acetyl-coA is transferred onto K532, located within ODD domain, by acetyltransferase ARD1. This modification further promotes interaction of HIF-1α with pVHL, in concert with proline hydroxylation. ARD1 is present in all the human tissues and its activity is not dependent on oxygen levels. However, the transcriptional and translational levels of ARD1 are reduced under hypoxia, causing decreased acetylation [50]. Replacing lysine with arginine enhances stability of HIF-1α while increasing acetylation promoted its degradation [51, 52].

Asparagine Hydroxylation

A third hydroxylation site on asparagine 803 (Asn/N 803) was identified on C-TAD of HIF-1α. This asparagyl residue is conserved on HIF-2α isoform (N851) [53, 54]. Unlike other posttranslational modifications already discussed, asparagine hydroxylation may not affect the stabilization of HIF. Rather, it promotes HIF activity *via* modulation of TADs. Under normoxic conditions, N803 is hydroxylated by a factor inhibiting HIF-1 (FIH-1), an oxygen dependent 2-OG dioxygenase requiring Fe^{2+} and ascorbate as cofactors [55-57]. It is considered as a second oxygen sensor and is localized in cytoplasm. Transcription of FIH-1 is not dependent on oxygen concentration [40]. Hydroxylation on N803 prevents interaction of HIF-1α with its coactivators CREB binding protein (CBP)/p300 due to steric inhibition. This coactivator recruitment is essential for transactivation of HIF-1α [58, 59].

Phosphorylation

Phosphorylation of HIF-1α by mitogen-activated protein kinase (MAPK) pathway appears to play a crucial role in regulating its activity and function. HIF-1α is highly phosphorylated *in vitro* by p42/p44 and p38 kinases [60-62]. Such activation promotes transcriptional activity of HIF-1. It is hypothesized that HIF-1β exhibits preferential binding to the phosphorylated HIF-1α protein [63]. Inhibitors of p42/44 protein kinases diminished hypoxia induced transcriptions of target genes, while their stimulation accelerates their translational activity [64]. Threonine (Thr/T) at residues 796 and 844 appear to be the potential phosphorylation sites in HIF-1α and HIF-2α, respectively [65].

Transactivation and Target Genes of HIF-1

In normoxic conditions, *de novo* synthesized cytoplasmic HIF-1α is rapidly hydroxylated (P402 and P564) and acetylated (L532). Later, HIF-1α is captured by pVHL and degraded by 26S proteasome [28, 42, 44]. However, in hypoxic conditions hydroxylation is inhibited. It becomes stabilized and then translocates into nucleus *via* NLS. The protein heterodimerizes with constitutively expressed HIF-1β, binds to the pentacore DNA binding sequence, recruits coactivators and activates transcription of various target genes (Fig. 2)

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

[66-68]. To date, more than hundred target genes of HIF-1 have been identified. The target genes play a key role in regulating angiogenesis, cell survival and proliferation, chemotherapy and radiation resistance, invasion and metastasis, genetic instability, immortalization, immune evasion, metabolism and stem cell maintenance [69-76]. Some important target genes have been listed in Table 1.

Angiogenesis is a complex signaling process involving multiple gene products [110]. Many of these genes are upregulated due to hypoxic insult [79, 111-114]. Hypoxia is an important regulatory factor directing angiogenic switch, with HIF-1 playing a predominant role in "flipping the switch" *via* direct transcriptional upregulation of vascular endothelial cell growth factor (VEGF). VEGF is a potent endothelial-specific mitogen. It interacts with its receptor (VEGFR) localized on endothelial cells and stimulates endothelial cell proliferation [112, 115-117]. Apart from VEGF induction, many complex mechanisms are also involved in HIF-1 mediated angiogenic control. The expression of α_{1B}-adrenergic receptor, adrenomedulin (ADM), angiopoietin 2, endothelin-1 (ET1), heme oxygenease-1 (HO-1), nitric oxide synthase, placental growth factor (PGF), platelet derived growth factor-B (PDGF-B) and stromal derived growth factor-1 (SDF-1) is regulated by hypoxia [105, 107-109, 118-122]. Also, expression of collagen prolyl hydroxylase, matrix metalloproteinases (MMPs) and plasminogen activator receptors and inhibitors (PAIs) under hypoxic control regulates matrix metabolism and vessel maturation (Fig. 3) [92, 99-100].

Role of HIF-1 in Ocular Diseases

Retina, a light sensitive tissue, forms the inner lining of posterior ocular segment and is metabolically one of the most active tissues in human body [123]. Continuous oxygen supply to retina facilitates high energy demand for sensitive and efficient transduction of images to readable neuronal signals [124, 125]. This neuronal function is executed by five different cell types including photoreceptors, bipolar cells, amacrine cells, horizontal cells and ganglion cells. Photoreceptors (cones and rods) play a vital role in phototransduction process. Cones mediate vision in bright light while rods mediate in dim light [126, 127]. Number of rods outweighs the number of cones by ~20 fold. Under dark conditions, a single rod cell requires 10^8 ATPs/second for ion homeostasis and signal transduction machinery. However under light exposure due to reduction in ion influx, energy requirement falls by 75% [128]. The energy requirement is met by oxidative phosphorylation process occurring in mitochondria, located within inner segment of photoreceptors [129]. Thus, oxygen concentration tightly controls retinal function.

In human a constant supply of oxygen is regulated *via* choroidal and retinal circulation. Since human retina is thick, these two separate and distinct systems act to facilitate diffusion. Choroidal vasculature nourishes the outer retina including retinal pigment epithelium (RPE) and photoreceptors while retinal vasculature perfuses the inner retinal layers. Choroidal circulation is highly vascularized. It is under low autoregulation and requires strong sympathetic control. Retinal circulation is relatively sparse, controlled by autoregulation and lacks sympathetic control. Arteriovenous oxygen gradient is also different between the two vasculatures [130, 131]. Further, the choroidal vessels are fenestrated while the retinal vessels lack fenestrations and express tight junctions [132].

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

Both vasculatures play an important role in regulating retinal physiology. Lack of oxygen supply can lead to vision threatening pathologies such as diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration and glaucoma. Despite the fact that initiating events are different, hypoxia with subsequent neovascularization is a characteristic phenomenon noticed with all these vascular diseases.

Diabetic Retinopathy

Diabetic retinopathy (DR) is a frequent secondary microvascular complication in patients with diabetes mellitus. It is one of the four major causes of visual impairment often leading to blindness [133, 134]. Almost 25-50% of diabetic patients exhibit retinopathy symptoms within the first 10-15 years and this number approaches nearly 100% within 30 years of diabetic onset [135, 136]. DR is characterized by biphasic progression with an initial non-proliferative (vaso-obliterative) phase followed by a proliferative (vaso-proliferative) phase. During initial stages, a persistent rise in blood glucose levels leads to a loss of intramural pericyte function. As a result small saccular capillary outpouchings, known as microaneurysms appear [137]. Intraretinal microvascular abnormalities, hemorrhages, edematous thickening of basement membrane, soft exudates and cotton wool spots are also observed [138-141]. Changes in vasculature and perturbations in oxygen tension lead to development of hypoxia, elevating the expression of angiogenic factors and subsequent neovascularization (proliferative phase) (Fig. 4A) [142]. The newly formed blood vessels are often fragile and permeable. Such vessels grow through the surface of retina into the vitreous and subsequent bleeding may lead to obstructed vision. Further, contraction of associated fibrovascular component may result in retinal detachment, vision loss and blindness [143-146].

The role of HIF-1 in the proliferative stage of DR has been clearly established. Mean oxygen tension is significantly lower in diabetics relative to non-diabetic patients in both lens (8.4 ± 0.7 mm Hg vs 10.7 ± 0.8 mm Hg) and vitreous cavity (5.7 ± 0.7 mm Hg vs 8.5 ± 0.6 mm Hg) [147]. Expression levels of HIF-1α and VEGF are elevated in diabetic preretinal membranes compared to non-diabetic idiopathic epiretinal membranes [148, 149]. Moreover, the production of VEGF and intercellular adhesion molecule (ICAM)-1 are diminished in a diabetic mice model lacking Hif-1α expression. It leads to much reduced vascular leakage and neovascularization in Hif-1α knockout mice relative to wild type mice [150]. These findings clearly suggest that alteration in HIF-1α pathway may be an attractive strategy for the treatment of DR.

Retinopathy of Prematurity

Retinopathy of prematurity (ROP), formerly known as retrolental fibroplasias, is the leading cause of visual impairment and blindness in children [151]. It was first described in early 1940s. This condition is associated with low gestational period, low birth weight and hyperoxia [152]. Human retinal vasculature begins to develop during 16th week of gestation and concludes at 40th week. Hence, premature infant's exhibit incompletely developed retinal vasculature and peripheral avascular zone. Oxygen supplementation (hyperoxia) is often needed in premature infants to overcome respiratory insufficiency. Such acute rise in oxygen tension can stimulate apoptosis of vascular endothelial cells and may cause vaso-

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

obliteration *via* generation of reactive oxygen species (ROS) (Phase I). Further, high perinatal levels of prostaglandins (PGD_2 and PGE_2) and nitric oxide (NO) accelerates oxidative metabolism. Reduced levels of antioxidants may induce complexity in disease pathology [153-156]. In a subsequent phase, the infant's vaso-obliterated retina undergoes hypoxic/ischemic stress. It triggers a series of events such as stabilization of HIF-1α and production of various proangiogenic factors resulting in neovascularization (Phase II) (Fig. 4B). In contrast to normal developmental vasculature, this pathological vasculature displays excessive, uncontrolled and misdirected growth towards vitreous and lens. It can cause fibrous scarring, retinal detachment and blindness [157-160].

Given the regulatory role of oxygen, it is evident that HIF plays a predominant role in the development and progression of ROP. In a mouse oxygen-induced retinopathy (OIR) model, the expression levels of HIF-1α and HIF-2α proteins peak after two hours of hypoxic exposure. However, HIF-1α is stabilized in neuronal cells and inner retinal layers whereas HIF-2α was upregulated in Muller glia and astrocytes [161]. Indeed, inhibition of Hif-1α and Vegf by gene therapy in mice ischemic retinopathy model inhibited neovascular tufts and nuclei compared to control hypoxia group [162]. Hence, altering the HIF-1α pathway may be beneficial than targeting other downstream factors.

Age-Related Macular Degeneration

Age-related macular degeneration (AMD) is the leading cause of blindness in patients over the age of 65. World Health Organization (WHO) global eye disease survey has revealed that more than 50 million people are affected with AMD and atleast one-third of them are blind or severely visually impaired [163]. Development of AMD is multifactorial including aging, smoking, genetic factors, obesity, hypertension and hypercholesterolemia [164-168]. The disease is characterized by degeneration of central retina leading to disturbed fine and color vision. AMD is classified into two clinical forms, non-exudative/dry AMD and exudative/wet AMD [169]. The dry phase accounts for 85 to 90% of the total cases. It is characterized by the presence of acellular polymorphous debris, termed as drusen, between the basal lamina of RPE and inner collagenous layers of Bruch's membrane (Fig. 4C). As AMD progresses geographical atrophy of photoreceptors and central retina are noticed [170, 171]. Although wet AMD represents 10 to 15% of total cases, it accounts for approximately 90% of vision loss. In certain cases, dry AMD progresses to wet AMD characterized by choroidal neovascularization (CNV). These abnormal blood vessels penetrate Bruch's membrane; grow into RPE and neural retina. This may lead to blurred vision, retinal detachment, fibrosis and complete vision loss [172, 173].

Cell and molecular biology studies have demonstrated that hypoxia, chronic oxidative stress and inflammation play a key role in AMD [174-176]. Hypoxia may result from higher oxygen consumption, resulting from increased metabolic activity of the inflamed retina or due to poor circulation in central macula, resulting from vessel stenosis and microthrombosis [177-179]. Also, thickening of Bruch's membrane and drusen formation further stabilizes HIF [180]. ROS also causes elevation in HIF protein expression and results in increased transcriptional activity of hypoxia regulated genes [181, 182]. Such hypoxic milieu contributes to progression of exudative AMD and development of CNV. Infact,

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

HIF-1α and HIF-2α expression were identified in endothelial cells and macrophages of choroidal neovascular membranes [183, 184].

Glaucoma

Glaucoma represents a multifactorial optic neuropathic disease [185]. It is classified into open and closed-angle depending on the anterior chamber angle. Open-angle glaucoma exhibits unobstructed and normal iridocorneal angle while the closed-angle glaucoma exhibits occlusion of the angle by the peripheral iris [186, 187]. Glaucoma is characterized by increased intraocular pressure, degeneration of retinal ganglion cells and axons. However, the exact role of hypoxia in the development of glaucoma is still unknown. Clinical observations have demonstrated retinal vascular abnormalities and impaired blood flow at the optic nerve head which may result in stabilization of hypoxic factors leading to retinal ganglion cell death [188, 189]. The expression of HIF-1α in control and glaucomatous human donor eyes was studied. Indeed, higher expression of the protein was noticed in retina and optic nerve head of glaucomatous eyes [190]. These findings clearly suggest the importance of hypoxia signaling mechanism in the pathogenesis of glaucoma.

Existing Anti-VEGF Therapeutics

Overproduction of VEGF plays an important role in pathogenesis of DR, ROP, AMD, neovascular glaucoma, central and branch retinal vein occlusion [191-194]. The human *VEGF-A* gene localized in chromosome 6p21.3 exhibits eight exons and four principal isoforms (121, 165, 189 and 206). The shorter isoform, $VEGF_{12}1$, is an acidic polypeptide and lacks heparin binding domain. The larger isoforms, $VEGF_{189}$ and $VEGF_{206}$, are highly basic and exhibit high affinity binding to heparin. The shorter isoform is freely diffusible while the larger isoforms are completely sequestered in the extracellular matrix. $VEGF_{165}$ exhibits intermediate properties, existing in both diffusible and bound forms [195]. The primary sources of VEGF in retina are RPE cells, Muller cells and ganglion cells. VEGF binds to two types of protein kinase activating receptors, VEGFR1 and VEGFR2. These high affinity receptors have been localized on retinal endothelial cells and pericytes [196-199]. Currently, anti-VEGF therapeutics are indicated in the treatment of ocular neovascular diseases. These include Pegaptanib sodium (Macugen; Eyetech Pharmaceuticals/Pfizer, NY), Ranibizumab (Leucentis; Genentech, CA), Bevacizumab (Avastin; Genentech, CA) and Aflibercept (VEGF Trap-Eye; Regeneron, NY).

Pegaptanib (50 kD) is the first anti-VEGF agent approved by US Food and Drug Administration (FDA) in 2001 for the treatment of exudative AMD. It is a 28-base ribonucleic acid aptamer, covalently linked to two branched polyethylene glycol (PEG-20kD) moieties. It binds to extracellular $VEGF_{165}$ with high affinity and prevents the interaction of VEGF with its receptor. Since pegaptanib binds specifically to only one isoform, it exhibits limited efficacy. Approval of this drug molecule began a new era in anti-VEGF therapy. Bevacizumab (149 kD) is a humanized recombinant full-length monoclonal antibody. It binds to all VEGF isoforms. Although not approved for specific intraocular use, bevacizumab has been indicated as an off-label therapeutic in the treatment of ocular diseases. Ranibizumab (48 kD) is the Fab fragment of the former, approved by US FDA in 2010 for treatment of macular edema and vein occlusion. Both these molecules bind all

Author Manuscript

forms of VEGF. Compared to bevacizumab, ranibizumab demonstrates 5-20 fold greater potency due to higher affinity and lack of immunogenicity. Aflibercept (115 kD) was approved by US FDA in 2011 for treatment of AMD. It is a recombinant fusion protein consisting of the VEGF binding domains of human VEGFR1 and VEGFR2 fused to the Fc domain of human immunoglobulin-G1. It acts as a decoy receptor binding free VEGF [200-203].

Although large molecule therapeutics appear to be promising, their long term usage must be considered with caution. A recent investigation by Kurihara *et al.*, reported the deleterious effects following deletion of *Vegfa* gene in adult mice. Choriocapillaris are completely attenuated following three days of RPE-specific *Vegf* inactivation. Further, cone photoreceptors were damaged and cone dysfunction was noticed. These dramatic secondary "off-target" effects of *Vegf* antagonism were not observed when *Hif1a*, *Epas1*, and *Hif1a/Epas1* were genetically ablated. The transcriptional mutants did not exhibit any morphological, functional, or transcriptional differences relative to control adult mice. Further, deletion of transcription factors reduced pathological angiogenesis in laser photocoagulation model of CNV. These studies clearly reinforce the strategy that molecules aiming at HIF pathway may be an alternative, safer and effective mode of treatment than attenuating VEGF levels alone [204, 205].

Development of HIF-1 Inhibitors

Significant research has been conducted in recent years to identify inhibitors of HIF-1 pathway. Based on their putative mechanism of action, HIF inhibitors may modulate eithe i) HIF-1α mRNA expression, ii) HIF-1α protein translation, iii) HIF-1α protein degradation, iv) HIF-1α DNA binding activity and v) HIF-1α transcriptional activity. Examples of HIF-1 inhibitors are summarized in Table 2 while few of them are described below.

HIF-1α mRNA Expression

It has been hypothesized that transcriptional level of HIF-1α is the rate limiting factor of HIF-1 activity under hypoxic conditions [240]. Hence, inhibitors that effect HIF-1α mRNA expression can lower the rate of HIF-1 translation. Chen *et al.*, have studied the role of HIF-1α inhibition by RNA interference (RNAi) with shRNA in BALB/C mouse model of corneal neovascularization. The effect of shRNA treatment was assessed by measuring mean neovascularization score. The mean score values were as follows: normal (0), control neovascular eyes (3.59 ± 1.1), saline treated (4.05 ± 0.75), vehicle-treated (3.64 ± 1.02) and RNAi- treated (1.13 ± 0.96). HIF-1α shRNA reduced neovascularization by more than 3 fold compared to control eyes. Further, the expression of angiogenic factors (VEGF and MMPs) and inflammatory mediator (IL-1β) was also diminished. In summary, this study confirmed the role of HIF-1α transcriptional inhibition in reducing corneal neovascularization and associated inflammation [241]. A similar study with RNAi of HIF-1α was performed by Jiang *et al.*, in C57BL/6J mice of ischemic retinopathy. The researchers have counted the number of neovascular nuclei on the vitreal side of inner limiting membrane. The number of nuclei per cross section were as follows: normoxia (0.05 ± 0.29), hypoxia (41 ± 2.8), vehicle-treated (41 ± 2.6) and siRNA-treated (28 ± 2.8). The number of neovessels significantly decreased in transfected group relative to hypoxic group

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

($p< 0.01$). This report clearly demonstrates the application of HIF-1α RNAi as a novel therapeutic for the treatment of neovascular eye diseases [162].

HIF-1α Protein Translation

Although the precise mechanism of HIF-1α protein translation in hypoxic conditions is not clear, several translational inhibitors have been identified. These molecules can directly inhibit translation or inhibit various signaling pathways (receptor tyrosine kinases, PI3K/AKT/mTOR and Ras-MAPK pathway). These signaling pathways play a predominant role in upregulating HIF-1α translation and thus inhibition of these growth factors can alter hypoxic regulation. Cardiac glycosides can inhibit HIF-1α protein translation and digoxin has been identified as a potent inhibitor in a cell-based reporter assay [242]. The effect of digoxin on ocular neovascularization was demonstrated by Yoshida *et al*., in C57BL/6 mice with ischemic retinopathy. Intraocular injection of digoxin lowered retinal neovascularization by almost 75% compared to saline group. Also, the area of CNV at Bruch's membrane was significantly lowered in presence of digoxin. Apart from inhibiting HIF-1α protein expression, digoxin also inhibited the expression of several angiogenic factors including VEGF, PDGF-B, SDF-1, VEGFR2, chemokine receptor (CXCR4) and Tie2 receptor in ischemic retina. This observation suggests that digoxin may offer advantages over VEGF antagonists in the treatment of neovascular diseases due to inhibition of several proangiogenic pathways. This study signifies that digoxin, a potent HIF-1α inhibitor, can possibly provide a better therapeutic intervention [243].

Genistein, a naturally occurring isoflavonoid, exhibits strong antiangiogenic activity. The underlying mechanism is hypothesized as inhibition of HIF-1α translation caused by inhibition of tyrosine kinases [213]. Wang *et al*., examined the effects of genistein on retinal neovascularization in C57BL/6 OIR mouse model. Number of vascular nuclei anterior to inner limiting membrane was quantified and data obtained was represented as: normoxia (0.76 ± 0.81), hypoxia (23.9 ± 4.4), genistein (50mg/kg) (20.9 ± 4.7), genistein (100mg/kg) (17.2 ± 4.0) and genistein (200mg/kg) (14.2 ± 3.2). The nuclei numbers were diminished by 87, 72 and 59% respectively, as the dose of genistein was increased. Further, dose-dependent reduction in HIF-1α and VEGF levels were also observed. This report suggests possible pharmacological application of genistein in ocular neovascularization [244].

HIF-1α Degradation

The molecular chaperone, heat shock protein 90 (Hsp90) is required for activity of various signaling proteins [245]. The interaction of Hsp90 with HIF-1α is required for proper conformational stability. Inhibitors of Hsp90 can promote degradation of HIF-1α *via* oxygen-independent proteasomal degradation [246]. Geldanamycin and its analogs (17-N-allylamino-17-demethoxygeldanamycin (17-AAG) and 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG/Deguelin)) may interfere with Hsp90/HIF-1α interaction by competing with the ATP binding site [247]. Kim *et al*. evaluated the potential of deguelin in the treatment of vaso-proliferative retinopathies. In an OIR mouse model, deguelin treated mice exhibited lower neovascularization as assessed by fluorescein angiography (Fig. 5). Further, the number of vascular lumens between posterior lens and anterior inner limiting membrane were estimated. Compared to control group the deguelin

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

injected group showed lower number of vascular lumens (19 ± 3.4 vs 4 ± 2.1). Moreover, deguelin treatment did not alter normal retinal morphology as evident by normal retinal thickness and lack of any inflammation in vitreous, retina or choroid. This data clearly implies that modulation of HIF pathway reduces retinal neovascularization without any retinal toxicity [248].

HIF-1α DNA Binding and Transcriptional Activity

Binding of active heterodimeric HIF-1 to the consensus -RCGTG- enhancer element of target genes is another crucial step necessary for transcription of hypoxia inducible target genes. Also, the interaction of coactivator p300 with HIF-1α is another potential mechanism required for transcriptional activity of HIF-1. These molecular pathways can also be targeted in the treatment of various neovascular diseases [236, 249, 250].

Conclusions and Future Perspectives

In summary, high levels of energy is required for proper retinal function. Any perturbations in oxygenation may lead to progression of several retinal degenerative diseases including DR, ROP and AMD. Mechanistic studies of cellular and molecular components of hypoxia signaling have opened a new era in the treatment of retinopathies. Given the role of HIF-1 in the etiology of these diseases, it is evident that manipulation of this pathway at various stages can lead to more effective treatment of oxygen-dependent ocular diseases. As discussed in this article, many inhibitors have been identified and evaluated both in *in vitro* cell culture and animal models. However, many HIF inhibitors exhibit significant side effects and toxicities due to lack of specificity. Hence development of HIF specific inhibitors and further work validating the pharmacological intervention of these inhibitors in retinal diseases and their translation from bench to bedside is necessary. Nonetheless, there is significant optimism that modulation of HIF pathway can provide new treatments for ocular neovascular diseases.

Acknowledgments

This study has been supported by NIH grants R01EY09171 and R01EY010659.

References

1. Semenza GL. Oxygen homeostasis. Wiley Interdiscip Rev Syst Biol Med. 2010; 2(3):336–61. [PubMed: 20836033]
2. Semenza GL. Life with oxygen. Science. 2007; 318(5847):62–4. [PubMed: 17916722]
3. Giaccia AJ, Simon MC, Johnson R. The biology of hypoxia: the role of oxygen sensing in development, normal function, and disease. Genes Dev. 2004; 18(18):2183–94. [PubMed: 15371333]
4. Lopez-Barneo J, Pardal R, Ortega-Saenz P. Cellular mechanism of oxygen sensing. Annu Rev Physiol. 2001; 63:259–87. [PubMed: 11181957]
5. Semenza GL, Nejfelt MK, Chi SM, Antonarakis SE. Hypoxia-inducible nuclear factors bind to an enhancer element located 3′ to the human erythropoietin gene. Proc Natl Acad Sci USA. 1991; 88(13):5680–4. [PubMed: 2062846]
6. Goldberg MA, Dunning SP, Bunn HF. Regulation of the erythropoietin gene: evidence that the oxygen sensor is a heme protein. Science. 1988; 242(4884):1412–5. [PubMed: 2849206]

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

7. Loenarz C, Coleman ML, Boleininger A, et al. The hypoxia-inducible transcription factor pathway regulates oxygen sensing in the simplest animal, Trichoplax adhaerens. EMBO Rep. 2011; 12(1): 63–70. [PubMed: 21109780]

8. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA. 1995; 92(12):5510–4. [PubMed: 7539918]

9. Reyes H, Reisz-Porszasz S, Hankinson O. Identification of the Ah receptor nuclear translocator protein (Arnt) as a component of the DNA binding form of the Ah receptor. Science. 1992; 256(5060):1193–5. [PubMed: 1317062]

10. Greer SN, Metcalf JL, Wang Y, Ohh M. The updated biology of hypoxia-inducible factor. EMBO J. 2012; 31(11):2448–60. [PubMed: 22562152]

11. Li Y, Ye D. Cancer therapy by targeting hypoxia-inducible factor-1. Curr Cancer Drug Targets. 2010; 10(7):782–96. [PubMed: 20578983]

12. Jiang BH, Rue E, Wang GL, Roe R, Semenza GL. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J Biol Chem. 1996; 271(30):17771–8. [PubMed: 8663540]

13. Huang LE, Gu J, Schau M, Bunn HF. Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain *via* the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA. 1998; 95(14):7987–92. [PubMed: 9653127]

14. Ruas JL, Poellinger L, Pereira T. Functional analysis of hypoxia-inducible factor-1 alpha-mediated transactivation. Identification of amino acid residues critical for transcriptional activation and/or interaction with CREB-binding protein. J Biol Chem. 2002; 277(41):38723–30. [PubMed: 12133832]

15. Jiang BH, Zheng JZ, Leung SW, Roe R, Semenza GL. Transactivation and inhibitory domains of hypoxia-inducible factor 1alpha. Modulation of transcriptional activity by oxygen tension. J Biol Chem. 1997; 272(31):19253–60. [PubMed: 9235919]

16. Kallio PJ, Okamoto K, O'Brien S, et al. Signal transduction in hypoxic cells: inducible nuclear translocation and recruitment of the CBP/p300 coactivator by the hypoxia-inducible factor-1alpha. EMBO J. 1998; 17(22):6573–86. [PubMed: 9822602]

17. Tian H, Hammer RE, Matsumoto AM, Russell DW, McKnight SL. The hypoxia-responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development. Genes Dev. 1998; 12(21):3320–4. [PubMed: 9808618]

18. Ema M, Taya S, Yokotani N, Sogawa K, Matsuda Y, Fujii-Kuriyama Y. A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development. Proc Natl Acad Sci USA. 1997; 94(9):4273–8. [PubMed: 9113979]

19. Tian H, McKnight SL, Russell DW. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev. 1997; 11(1):72–82. [PubMed: 9000051]

20. Hara S, Hamada J, Kobayashi C, Kondo Y, Imura N. Expression and characterization of hypoxia-inducible factor (HIF)-3alpha in human kidney: suppression of HIF-mediated gene expression by HIF-3alpha. Biochem Biophys Res Commun. 2001; 287(4):808–13. [PubMed: 11573933]

21. Gu YZ, Moran SM, Hogenesch JB, Wartman L, Bradfield CA. Molecular characterization and chromosomal localization of a third alpha-class hypoxia inducible factor subunit, HIF3alpha. Gene Expr. 1998; 7(3):205–13. [PubMed: 9840812]

22. Makino Y, Kanopka A, Wilson WJ, Tanaka H, Poellinger L. Inhibitory PAS domain protein (IPAS) is a hypoxia-inducible splicing variant of the hypoxia-inducible factor-3alpha locus. J Biol Chem. 2002; 277(36):32405–8. [PubMed: 12119283]

23. Makino Y, Cao R, Svensson K, et al. Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature. 2001; 414(6863):550–4. [PubMed: 11734856]

24. Wiesener MS, Turley H, Allen WE, et al. Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1alpha. Blood. 1998; 92(7):2260–8. [PubMed: 9746763]

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

25. Kallio PJ, Pongratz I, Gradin K, McGuire J, Poellinger L. Activation of hypoxia-inducible factor 1alpha: posttranscriptional regulation and conformational change by recruitment of the Arnt transcription factor. Proc Natl Acad Sci USA. 1997; 94(11):5667–72. [PubMed: 9159130]
26. Brahimi-Horn C, Mazure N, Pouyssegur J. Signalling *via* the hypoxia-inducible factor-1alpha requires multiple posttranslational modifications. Cell Signal. 2005; 17(1):1–9. [PubMed: 15451019]
27. Welsh SJ, Powis G. Hypoxia inducible factor as a cancer drug target. Curr Cancer Drug Targets. 2003; 3(6):391–405. [PubMed: 14683498]
28. Ivan M, Kondo K, Yang H, et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science. 2001; 292(5516):464–8. [PubMed: 11292862]
29. Jaakkola P, Mole DR, Tian YM, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001; 292(5516):468–72. [PubMed: 11292861]
30. Masson N, Ratcliffe PJ. HIF prolyl and asparaginyl hydroxylases in the biological response to intracellular O(2) levels. J Cell Sci. 2003; 116(Pt 15):3041–9. [PubMed: 12829734]
31. Masson N, Willam C, Maxwell PH, Pugh CW, Ratcliffe PJ. Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. EMBO J. 2001; 20(18):5197–206. [PubMed: 11566883]
32. Srinivas V, Zhang LP, Zhu XH, Caro J. Characterization of an oxygen/redox-dependent degradation domain of hypoxia-inducible factor alpha (HIF-alpha) proteins. Biochem Biophys Res Commun. 1999; 260(2):557–61. [PubMed: 10403805]
33. Huang J, Zhao Q, Mooney SM, Lee FS. Sequence determinants in hypoxia-inducible factor-1alpha for hydroxylation by the prolyl hydroxylases PHD1, PHD2, and PHD3. J Biol Chem. 2002; 277(42):39792–800. [PubMed: 12181324]
34. Schofield CJ, Zhang Z. Structural and mechanistic studies on 2-oxoglutarate-dependent oxygenases and related enzymes. Curr Opin Struct Biol. 1999; 9(6):722–31. [PubMed: 10607676]
35. Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science. 2001; 294(5545):1337–40. [PubMed: 11598268]
36. Lando D, Gorman JJ, Whitelaw ML, Peet DJ. Oxygen-dependent regulation of hypoxia-inducible factors by prolyl and asparaginyl hydroxylation. Eur J Biochem. 2003; 270(5):781–90. [PubMed: 12603311]
37. Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci USA. 1996; 93(25):14765–70. [PubMed: 8962129]
38. Epstein AC, Gleadle JM, McNeill LA, et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell. 2001; 107(1):43–54. [PubMed: 11595184]
39. Berra E, Benizri E, Ginouves A, Volmat V, Roux D, Pouyssegur J. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J. 2003; 22(16):4082–90. [PubMed: 12912907]
40. Metzen E, Berchner-Pfannschmidt U, Stengel P, et al. Intracellular localisation of human HIF-1 alpha hydroxylases: implications for oxygen sensing. J Cell Sci. 2003; 116(Pt 7):1319–26. [PubMed: 12615973]
41. Hon WC, Wilson MI, Harlos K, et al. Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL. Nature. 2002; 417(6892):975–8. [PubMed: 12050673]
42. Min JH, Yang H, Ivan M, Gertler F, Kaelin WG Jr, Pavletich NP. Structure of an HIF-1alpha - pVHL complex: hydroxyproline recognition in signaling. Science. 2002; 296(5574):1886–9. [PubMed: 12004076]
43. Ivan M, Kaelin WG Jr. The von Hippel-Lindau tumor suppressor protein. Curr Opin Genet Dev. 2001; 11(1):27–34. [PubMed: 11163147]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

44. Kamura T, Sato S, Iwai K, Czyzyk-Krzeska M, Conaway RC, Conaway JW. Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci USA. 2000; 97(19):10430–5. [PubMed: 10973499]
45. Groulx I, Lee S. Oxygen-dependent ubiquitination and degradation of hypoxia-inducible factor requires nuclear-cytoplasmic trafficking of the von Hippel-Lindau tumor suppressor protein. Mol Cell Biol. 2002; 22(15):5319–36. [PubMed: 12101228]
46. Berra E, Roux D, Richard DE, Pouyssegur J. Hypoxia-inducible factor-1 alpha (HIF-1 alpha) escapes O(2)-driven proteasomal degradation irrespective of its subcellular localization: nucleus or cytoplasm. EMBO Rep. 2001; 2(7):615–20. [PubMed: 11454738]
47. Yu F, White SB, Zhao Q, Lee FS. Dynamic, site-specific interaction of hypoxia-inducible factor-1alpha with the von Hippel-Lindau tumor suppressor protein. Cancer Res. 2001; 61(10): 4136–42. [PubMed: 11358837]
48. Krieg M, Haas R, Brauch H, Acker T, Flamme I, Plate KH. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene. 2000; 19(48):5435–43. [PubMed: 11114720]
49. Cockman ME, Masson N, Mole DR, et al. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem. 2000; 275(33): 25733–41. [PubMed: 10823831]
50. Jeong JW, Bae MK, Ahn MY, et al. Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell. 2002; 111(5):709–20. [PubMed: 12464182]
51. Kim MS, Kwon HJ, Lee YM, et al. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med. 2001; 7(4):437–43. [PubMed: 11283670]
52. Tanimoto K, Makino Y, Pereira T, Poellinger L. Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. EMBO J. 2000; 19(16):4298–309. [PubMed: 10944113]
53. Sang N, Fang J, Srinivas V, Leshchinsky I, Caro J. Carboxyl-terminal transactivation activity of hypoxia-inducible factor 1 alpha is governed by a von Hippel-Lindau protein-independent, hydroxylation-regulated association with p300/CBP. Mol Cell Biol. 2002; 22(9):2984–92. [PubMed: 11940656]
54. Lando D, Peet DJ, Whelan DA, Gorman JJ, Whitelaw ML. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science. 2002; 295(5556):858–61. [PubMed: 11823643]
55. Lando D, Peet DJ, Gorman JJ, Whelan DA, Whitelaw ML, Bruick RK. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev. 2002; 16(12):1466–71. [PubMed: 12080085]
56. Hewitson KS, McNeill LA, Riordan MV, et al. Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family. J Biol Chem. 2002; 277(29):26351–5. [PubMed: 12042299]
57. Mahon PC, Hirota K, Semenza GL. FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev. 2001; 15(20):2675–86. [PubMed: 11641274]
58. Freedman SJ, Sun ZY, Poy F, Kung AL, Livingston DM, Wagner G, et al. Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1 alpha. Proc Natl Acad Sci USA. 2002; 99(8):5367–72. [PubMed: 11959990]
59. Dames SA, Martinez-Yamout M, De Guzman RN, Dyson HJ, Wright PE. Structural basis for Hif-1 alpha/CBP recognition in the cellular hypoxic response. Proc Natl Acad Sci USA. 2002; 99(8): 5271–6. [PubMed: 11959977]
60. Minet E, Michel G, Mottet D, Raes M, Michiels C. Transduction pathways involved in Hypoxia-Inducible Factor-1 phosphorylation and activation. Free Radic Biol Med. 2001; 31(7):847–55. [PubMed: 11585703]
61. Sodhi A, Montaner S, Patel V, et al. The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1alpha. Cancer Res. 2000; 60(17):4873–80. [PubMed: 10987301]

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

62. Richard DE, Berra E, Gothie E, Roux D, Pouyssegur J. p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1. J Biol Chem. 1999; 274(46):32631–7. [PubMed: 10551817]
63. Suzuki H, Tomida A, Tsuruo T. Dephosphorylated hypoxia-inducible factor 1alpha as a mediator of p53-dependent apoptosis during hypoxia. Oncogene. 2001; 20(41):5779–88. [PubMed: 11593383]
64. Hur E, Chang KY, Lee E, Lee SK, Park H. Mitogen-activated protein kinase kinase inhibitor PD98059 blocks the trans-activation but not the stabilization or DNA binding ability of hypoxia-inducible factor-1alpha. Mol Pharmacol. 2001; 59(5):1216–24. [PubMed: 11306706]
65. Gradin K, Takasaki C, Fujii-Kuriyama Y, Sogawa K. The transcriptional activation function of the HIF-like factor requires phosphorylation at a conserved threonine. J Biol Chem. 2002; 277(26): 23508–14. [PubMed: 11983697]
66. Wenger RH, Stiehl DP, Camenisch G. Integration of oxygen signaling at the consensus HRE. Sci STKE. 2005; 2005(306):re12. [PubMed: 16234508]
67. Huang LE, Arany Z, Livingston DM, Bunn HF. Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit. J Biol Chem. 1996; 271(50):32253–9. [PubMed: 8943284]
68. Pugh CW, Tan CC, Jones RW, Ratcliffe PJ. Functional analysis of an oxygen-regulated transcriptional enhancer lying 3′ to the mouse erythropoietin gene. Proc Natl Acad Sci USA. 1991; 88(23):10553–7. [PubMed: 1961720]
69. Barnhart BC, Simon MC. Metastasis and stem cell pathways. Cancer Metastasis Rev. 2007; 26(2): 261–71. [PubMed: 17647111]
70. Sullivan R, Graham CH. Hypoxia-driven selection of the metastatic phenotype. Cancer Metastasis Rev. 2007; 26(2):319–31. [PubMed: 17458507]
71. Chan DA, Giaccia AJ. Hypoxia, gene expression, and metastasis. Cancer Metastasis Rev. 2007; 26(2):333–9. [PubMed: 17458506]
72. Moeller BJ, Richardson RA, Dewhirst MW. Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment. Cancer Metastasis Rev. 2007; 26(2):241–8. [PubMed: 17440683]
73. Bindra RS, Crosby ME, Glazer PM. Regulation of DNA repair in hypoxic cancer cells. Cancer Metastasis Rev. 2007; 26(2):249–60. [PubMed: 17415527]
74. Swietach P, Vaughan-Jones RD, Harris AL. Regulation of tumor pH and the role of carbonic anhydrase 9. Cancer Metastasis Rev. 2007; 26(2):299–310. [PubMed: 17415526]
75. Lukashev D, Ohta A, Sitkovsky M. Hypoxia-dependent anti-inflammatory pathways in protection of cancerous tissues. Cancer Metastasis Rev. 2007; 26(2):273–9. [PubMed: 17404693]
76. Liao D, Corle C, Seagroves TN, Johnson RS. Hypoxia-inducible factor-1alpha is a key regulator of metastasis in a transgenic model of cancer initiation and progression. Cancer Res. 2007; 67(2): 563–72. [PubMed: 17234764]
77. LeCouter J, Kowalski J, Foster J, et al. Identification of an angiogenic mitogen selective for endocrine gland endothelium. Nature. 2001; 412(6850):877–84. [PubMed: 11528470]
78. Caniggia I, Mostachfi H, Winter J, et al. Hypoxia-inducible factor-1 mediates the biological effects of oxygen on human trophoblast differentiation through TGFbeta(3). J Clin Invest. 2000; 105(5): 577–87. [PubMed: 10712429]
79. Levy AP, Levy NS, Wegner S, Goldberg MA. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J Biol Chem. 1995; 270(22):13333–40. [PubMed: 7768934]
80. Gerber HP, Condorelli F, Park J, Ferrara N. Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. J Biol Chem. 1997; 272(38):23659–67. [PubMed: 9295307]
81. Bruick RK. Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia. Proc Natl Acad Sci USA. 2000; 97(16):9082–7. [PubMed: 10922063]
82. Feldser D, Agani F, Iyer NV, Pak B, Ferreira G, Semenza GL. Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-like growth factor 2. Cancer Res. 1999; 59(16):3915–8. [PubMed: 10463582]

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

83. Tazuke SI, Mazure NM, Sugawara J, et al. Hypoxia stimulates insulin-like growth factor binding protein 1 (IGFBP-1) gene expression in HepG2 cells: a possible model for IGFBP-1 expression in fetal hypoxia. Proc Natl Acad Sci USA. 1998; 95(17):10188–93. [PubMed: 9707622]
84. Krishnamachary B, Berg-Dixon S, Kelly B, et al. Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res. 2003; 63(5):1138–43. [PubMed: 12615733]
85. Lofstedt T, Jogi A, Sigvardsson M, et al. Induction of ID2 expression by hypoxia-inducible factor-1: a role in dedifferentiation of hypoxic neuroblastoma cells. J Biol Chem. 2004; 279(38): 39223–31. [PubMed: 15252039]
86. Krishnamurthy P, Ross DD, Nakanishi T, et al. The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. J Biol Chem. 2004; 279(23):24218–25. [PubMed: 15044468]
87. Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, Colgan SP. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res. 2002; 62(12):3387–94. [PubMed: 12067980]
88. Grosfeld A, Andre J, Hauguel-De Mouzon S, Berra E, Pouyssegur J, Guerre-Millo M. Hypoxia-inducible factor 1 transactivates the human leptin gene promoter. J Biol Chem. 2002; 277(45): 42953–7. [PubMed: 12215445]
89. Koshiji M, To KK, Hammer S, et al. HIF-1alpha induces genetic instability by transcriptionally downregulating MutSalpha expression. Mol Cell. 2005; 17(6):793–803. [PubMed: 15780936]
90. Iyer NV, Kotch LE, Agani F, et al. Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev. 1998; 12(2):149–62. [PubMed: 9436976]
91. Wood SM, Wiesener MS, Yeates KM, et al. Selection and analysis of a mutant cell line defective in the hypoxia-inducible factor-1 alpha-subunit (HIF-1alpha). Characterization of hif-1alpha-dependent and -independent hypoxia-inducible gene expression. J Biol Chem. 1998; 273(14): 8360–8. [PubMed: 9525945]
92. Hogenesch JB, Gu YZ, Moran SM. The basic helix-loop-helix-PAS protein MOP9 is a brain-specific heterodimeric partner of circadian and hypoxia factors. J Neurosci. 2000; 20(13):RC83. [PubMed: 10864977]
93. Semenza GL, Roth PH, Fang HM, Wang GL. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J Biol Chem. 1994; 269(38):23757–63. [PubMed: 8089148]
94. Fu L, Chen L, Yang J, Ye T, Chen Y, Fang J. HIF-1alpha-induced histone demethylase JMJD2B contributes to the malignant phenotype of colorectal cancer cells *via* an epigenetic mechanism. Carcinogenesis. 2012; 33(9):1664–73. [PubMed: 22745382]
95. Mukhopadhyay CK, Mazumder B, Fox PL. Role of hypoxia-inducible factor-1 in transcriptional activation of ceruloplasmin by iron deficiency. J Biol Chem. 2000; 275(28):21048–54. [PubMed: 10777486]
96. Rolfs A, Kvietikova I, Gassmann M, Wenger RH. Oxygen-regulated transferrin expression is mediated by hypoxia-inducible factor-1. J Biol Chem. 1997; 272(32):20055–62. [PubMed: 9242677]
97. Lok CN, Ponka P. Identification of a hypoxia response element in the transferrin receptor gene. J Biol Chem. 1999; 274(34):24147–52. [PubMed: 10446188]
98. Takahashi Y, Takahashi S, Shiga Y, Yoshimi T, Miura T. Hypoxic induction of prolyl 4-hydroxylase alpha (I) in cultured cells. J Biol Chem. 2000; 275(19):14139–46. [PubMed: 10799490]
99. Ben-Yosef Y, Lahat N, Shapiro S, Bitterman H, Miller A. Regulation of endothelial matrix metalloproteinase-2 by hypoxia/reoxygenation. Circ Res. 2002; 90(7):784–91. [PubMed: 11964371]
100. Kietzmann T, Roth U, Jungermann K. Induction of the plasminogen activator inhibitor-1 gene expression by mild hypoxia *via* a hypoxia response element binding the hypoxia-inducible factor-1 in rat hepatocytes. Blood. 1999; 94(12):4177–85. [PubMed: 10590062]
101. Cowden Dahl KD, Robertson SE, Weaver VM, Simon MC. Hypoxia-inducible factor regulates alphavbeta3 integrin cell surface expression. Mol Biol Cell. 2005; 16(4):1901–12. [PubMed: 15689487]

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

102. Zagzag D, Lukyanov Y, Lan L, et al. Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion. Lab Invest. 2006; 86(12):1221–32. [PubMed: 17075581]

103. Wykoff CC, Beasley NJ, Watson PH, et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res. 2000; 60(24):7075–83. [PubMed: 11156414]

104. Oikawa M, Abe M, Kurosawa H, Hida W, Shirato K, Sato Y. Hypoxia induces transcription factor ETS-1 *via* the activity of hypoxia-inducible factor-1. Biochem Biophys Res Commun. 2001; 289(1):39–43. [PubMed: 11708773]

105. Eckhart AD, Yang N, Xin X, Faber JE. Characterization of the alpha1B-adrenergic receptor gene promoter region and hypoxia regulatory elements in vascular smooth muscle. Proc Natl Acad Sci USA. 1997; 94(17):9487–92. [PubMed: 9256509]

106. Cormier-Regard S, Nguyen SV, Claycomb WC. Adrenomedullin gene expression is developmentally regulated and induced by hypoxia in rat ventricular cardiac myocytes. J Biol Chem. 1998; 273(28):17787–92. [PubMed: 9651380]

107. Hu J, Discher DJ, Bishopric NH, Webster KA. Hypoxia regulates expression of the endothelin-1 gene through a proximal hypoxia-inducible factor-1 binding site on the antisense strand. Biochem Biophys Res Commun. 1998; 245(3):894–9. [PubMed: 9588211]

108. Lee PJ, Jiang BH, Chin BY, et al. Hypoxia-inducible factor-1 mediates transcriptional activation of the heme oxygenase-1 gene in response to hypoxia. J Biol Chem. 1997; 272(9):5375–81. [PubMed: 9038135]

109. Melillo G, Musso T, Sica A, Taylor LS, Cox GW, Varesio L. A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter. J Exp Med. 1995; 182(6):1683–93. [PubMed: 7500013]

110. Conway EM, Collen D, Carmeliet P. Molecular mechanisms of blood vessel growth. Cardiovasc Res. 2001; 49(3):507–21. [PubMed: 11166264]

111. Giordano FJ, Johnson RS. Angiogenesis: the role of the microenvironment in flipping the switch. Curr Opin Genet Dev. 2001; 11(1):35–40. [PubMed: 11163148]

112. Berra E, Milanini J, Richard DE, et al. Signaling angiogenesis *via* p42/p44 MAP kinase and hypoxia. Biochem Pharmacol. 2000; 60(8):1171–8. [PubMed: 11007955]

113. Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol. 1996; 16(9):4604–13. [PubMed: 8756616]

114. Bunn HF, Poyton RO. Oxygen sensing and molecular adaptation to hypoxia. Physiol Rev. 1996; 76(3):839–85. [PubMed: 8757790]

115. Josko J, Gwozdz B, Jedrzejowska-Szypulka H, Hendryk S. Vascular endothelial growth factor (VEGF) and its effect on angiogenesis. Med Sci Monit. 2000; 6(5):1047–52. [PubMed: 11208453]

116. Harris AL. von Hippel-Lindau syndrome: target for anti-vascular endothelial growth factor (VEGF) receptor therapy. Oncologist. 2000; 5(Suppl 1):32–6. [PubMed: 10804089]

117. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999; 13(1):9–22. [PubMed: 9872925]

118. Nguyen SV, Claycomb WC. Hypoxia regulates the expression of the adrenomedullin and HIF-1 genes in cultured HL-1 cardiomyocytes. Biochem Biophys Res Commun. 1999; 265(2):382–6. [PubMed: 10558876]

119. Lima e Silva R, Shen J, Hackett SF, et al. The SDF-1/CXCR4 ligand/receptor pair is an important contributor to several types of ocular neovascularization. FASEB J. 2007; 21(12):3219–30. [PubMed: 17522382]

120. Rakic JM, Lambert V, Devy L, et al. Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci. 2003; 44(7):3186–93. [PubMed: 12824270]

121. Seo MS, Okamoto N, Vinores MA, et al. Photoreceptor-specific expression of platelet-derived growth factor-B results in traction retinal detachment. Am J Pathol. 2000; 157(3):995–1005. [PubMed: 10980138]

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

122. Hackett SF, Ozaki H, Strauss RW, et al. Angiopoietin 2 expression in the retina: upregulation during physiologic and pathologic neovascularization. J Cell Physiol. 2000; 184(3):275–84. [PubMed: 10911358]
123. Ames A 3rd. Energy requirements of CNS cells as related to their function and to their vulnerability to ischemia: a commentary based on studies on retina. Can J Physiol Pharmacol. 1992; 70(Suppl 1):S158–64. [PubMed: 1295666]
124. Campochiaro PA. Ocular neovascularization. J Mol Med (Berl). 2013; 91(3):311–21. [PubMed: 23329331]
125. Caprara C, Grimm C. From oxygen to erythropoietin: relevance of hypoxia for retinal development, health and disease. Prog Retin Eye Res. 2012; 31(1):89–119. [PubMed: 22108059]
126. Sung CH, Chuang JZ. The cell biology of vision. J Cell Biol. 2010; 190(6):953–63. [PubMed: 20855501]
127. Baccus SA. Timing and computation in inner retinal circuitry. Annu Rev Physiol. 2007; 69:271–90. [PubMed: 17059359]
128. Okawa H, Sampath AP, Laughlin SB, Fain GL. ATP consumption by mammalian rod photoreceptors in darkness and in light. Curr Biol. 2008; 18(24):1917–21. [PubMed: 19084410]
129. Stone J, van Driel D, Valter K, Rees S, Provis J. The locations of mitochondria in mammalian photoreceptors: relation to retinal vasculature. Brain Res. 2008; 1189:58–69. [PubMed: 18048005]
130. Flammer J, Mozaffarieh M. Autoregulation, a balancing act between supply and demand. Can J Ophthalmol. 2008; 43(3):317–21. [PubMed: 18493273]
131. Pournaras CJ, Rungger-Brandle E, Riva CE, Hardarson SH, Stefansson E. Regulation of retinal blood flow in health and disease. Prog Retin Eye Res. 2008; 27(3):284–330. [PubMed: 18448380]
132. Saint-Geniez M, D'Amore PA. Development and pathology of the hyaloid, choroidal and retinal vasculature. Int J Dev Biol. 2004; 48(8-9):1045–58. [PubMed: 15558494]
133. Kocur I, Resnikoff S. Visual impairment and blindness in Europe and their prevention. Br J Ophthalmol. 2002; 86(7):716–22. [PubMed: 12084735]
134. Ferris FL 3rd, Davis MD, Aiello LM. Treatment of diabetic retinopathy. N Engl J Med. 1999; 341(9):667–78. [PubMed: 10460819]
135. Crawford TN, Alfaro DV 3rd, Kerrison JB, Jablon EP. Diabetic retinopathy and angiogenesis. Curr Diabetes Rev. 2009; 5(1):8–13. [PubMed: 19199892]
136. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001; 414(6865):782–7. [PubMed: 11742409]
137. Bhavsar AR. Diabetic retinopathy: the latest in current management. Retina. 2006; 26(6 Suppl):S71–9. [PubMed: 16832305]
138. Arden GB, Sivaprasad S. Hypoxia and oxidative stress in the causation of diabetic retinopathy. Curr Diabetes Rev. 2011; 7(5):291–304. [PubMed: 21916837]
139. Wilkinson-Berka JL. Angiotensin and diabetic retinopathy. Int J Biochem Cell Biol. 2006; 38(5-6):752–65. [PubMed: 16165393]
140. Engerman RL, Kern TS. Retinopathy in animal models of diabetes. Diabetes Metab Rev. 1995; 11(2):109–20. [PubMed: 7555563]
141. Stitt AW, Anderson HR, Gardiner TA, Archer DB. Diabetic retinopathy: quantitative variation in capillary basement membrane thickening in arterial or venous environments. Br J Ophthalmol. 1994; 78(2):133–7. [PubMed: 8123622]
142. Bursell SE, Clermont AC, Kinsley BT, Simonson DC, Aiello LM, Wolpert HA. Retinal blood flow changes in patients with insulin-dependent diabetes mellitus and no diabetic retinopathy. Invest Ophthalmol Vis Sci. 1996; 37(5):886–97. [PubMed: 8603873]
143. Josifova T, Plestina-Borjan I, Henrich PB. Proliferative diabetic retinopathy: predictive and preventive measures at hypoxia induced retinal changes. The EPMA journal. 2010; 1(1):73–7. [PubMed: 23199042]
144. Morello CM. Etiology and natural history of diabetic retinopathy: an overview. Am J Health Syst Pharm. 2007; 64(17 Suppl 12):S3–7. [PubMed: 17720892]

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

145. Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: a systematic review. JAMA. 2007; 298(8):902–16. [PubMed: 17712074]
146. Watkins PJ. Retinopathy. BMJ. 2003; 326(7395):924–6. [PubMed: 12714476]
147. Holekamp NM, Shui YB, Beebe D. Lower intraocular oxygen tension in diabetic patients: possible contribution to decreased incidence of nuclear sclerotic cataract. Am J Ophthalmol. 2006; 141(6):1027–32. [PubMed: 16765670]
148. Lim JI, Spee C, Hinton DR. A comparison of hypoxia-inducible factor-alpha in surgically excised neovascular membranes of patients with diabetes compared with idiopathic epiretinal membranes in nondiabetic patients. Retina. 2010; 30(9):1472–8. [PubMed: 20811317]
149. Abu El-Asrar AM, Missotten L, Geboes K. Expression of hypoxia-inducible factor-1alpha and the protein products of its target genes in diabetic fibrovascular epiretinal membranes. Br J Ophthalmol. 2007; 91(6):822–6. [PubMed: 17229797]
150. Lin M, Chen Y, Jin J, et al. Ischaemia-induced retinal neovascularisation and diabetic retinopathy in mice with conditional knockout of hypoxia-inducible factor-1 in retinal Muller cells. Diabetologia. 2011; 54(6):1554–66. [PubMed: 21360191]
151. Gilbert C. Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control. Early Hum Dev. 2008; 84(2):77–82. [PubMed: 18234457]
152. Smith LE. Pathogenesis of retinopathy of prematurity. Semin Neonatol. 2003; 8(6):469–73. [PubMed: 15001119]
153. Kuriyama H, Waki M, Nakagawa M, Tsuda M. Involvement of oxygen free radicals in experimental retinal ischemia and the selective vulnerability of retinal damage. Ophthalmic Res. 2001; 33(4):196–202. [PubMed: 11464071]
154. Hardy P, Dumont I, Bhattacharya M, et al. Oxidants, nitric oxide and prostanoids in the developing ocular vasculature: a basis for ischemic retinopathy. Cardiovasc Res. 2000; 47(3): 489–509. [PubMed: 10963722]
155. Hardy P, Abran D, Li DY, Fernandez H, Varma DR, Chemtob S. Free radicals in retinal and choroidal blood flow autoregulation in the piglet: interaction with prostaglandins. Invest Ophthalmol Vis Sci. 1994; 35(2):580–91. [PubMed: 8113009]
156. Flynn JT, Bancalari E, Snyder ES, et al. A cohort study of transcutaneous oxygen tension and the incidence and severity of retinopathy of prematurity. N Engl J Med. 1992; 326(16):1050–4. [PubMed: 1549150]
157. Sapieha P, Joyal JS, Rivera JC, et al. Retinopathy of prematurity: understanding ischemic retinal vasculopathies at an extreme of life. J Clin Invest. 2010; 120(9):3022–32. [PubMed: 20811158]
158. Kermorvant-Duchemin E, Sapieha P, Sirinyan M, et al. Understanding ischemic retinopathies: emerging concepts from oxygen-induced retinopathy. Doc Ophthalmol. 2010; 120(1):51–60. [PubMed: 19882183]
159. Smith LE. Through the eyes of a child: understanding retinopathy through ROP the Friedenwald lecture. Invest Ophthalmol Vis Sci. 2008; 49(12):5177–82. [PubMed: 18708611]
160. Chen J, Smith LE. Retinopathy of prematurity. Angiogenesis. 2007; 10(2):133–40. [PubMed: 17332988]
161. Mowat FM, Luhmann UF, Smith AJ, et al. HIF-1alpha and HIF-2alpha are differentially activated in distinct cell populations in retinal ischaemia. PloS one. 2010; 5(6):e11103. [PubMed: 20559438]
162. Jiang J, Xia XB, Xu HZ, et al. Inhibition of retinal neovascularization by gene transfer of small interfering RNA targeting HIF-1alpha and VEGF. J Cell Physiol. 2009; 218(1):66–74. [PubMed: 18767037]
163. Gehrs KM, Anderson DH, Johnson LV, Hageman GS. Age-related macular degeneration--emerging pathogenetic and therapeutic concepts. Ann Med. 2006; 38(7):450–71. [PubMed: 17101537]
164. Adams MK, Simpson JA, Aung KZ, Makeyeva GA, Giles GG, English DR, et al. Abdominal obesity and age-related macular degeneration. Am J Epidemiol. 2011; 173(11):1246–55. [PubMed: 21422060]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

165. Reynolds R, Rosner B, Seddon JM. Serum lipid biomarkers and hepatic lipase gene associations with age-related macular degeneration. Ophthalmology. 2010; 117(10):1989–95. [PubMed: 20888482]
166. Klein R, Cruickshanks KJ, Nash SD, et al. The prevalence of age-related macular degeneration and associated risk factors. Arch Ophthalmol. 2010; 128(6):750–8. [PubMed: 20547953]
167. Tolppanen AM, Nevalainen T, Kolehmainen M, et al. Single nucleotide polymorphisms of the tenomodulin gene (TNMD) in age-related macular degeneration. Mol Vis. 2009; 15:762–70. [PubMed: 19381347]
168. van Leeuwen R, Ikram MK, Vingerling JR, Witteman JC, Hofman A, de Jong PT. Blood pressure, atherosclerosis, and the incidence of age-related maculopathy: the Rotterdam Study. Invest Ophthalmol Vis Sci. 2003; 44(9):3771–7. [PubMed: 12939290]
169. Cook HL, Patel PJ, Tufail A. Age-related macular degeneration: diagnosis and management. Br Med Bull. 2008; 85:127–49. [PubMed: 18334518]
170. Algvere PV, Seregard S. Drusen maculopathy: a risk factor for AMD. Can we prevent visual loss? Acta Ophthalmol Scand. 2003; 81(5):427–9. [PubMed: 14510786]
171. Ambati J, Ambati BK, Yoo SH, Ianchulev S, Adamis AP. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol. 2003; 48(3):257–93. [PubMed: 12745003]
172. Bhutto I, Lutty G. Understanding age-related macular degeneration (AMD): relationships between the photoreceptor/retinal pigment epithelium/Bruch's membrane/choriocapillaris complex. Mol Aspects Med. 2012; 33(4):295–317. [PubMed: 22542780]
173. Ayoub T, Patel N. Age-related macular degeneration. J R Soc Med. 2009; 102(2):56–61. [PubMed: 19208869]
174. Donoso LA, Kim D, Frost A, Callahan A, Hageman G. The role of inflammation in the pathogenesis of age-related macular degeneration. Surv Ophthalmol. 2006; 51(2):137–52. [PubMed: 16500214]
175. Beatty S, Koh H, Phil M, Henson D, Boulton M. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol. 2000; 45(2):115–34. [PubMed: 11033038]
176. Arjamaa O, Nikinmaa M, Salminen A, Kaarniranta K. Regulatory role of HIF-1alpha in the pathogenesis of age-related macular degeneration (AMD). Ageing research reviews. 2009; 8(4): 349–58. [PubMed: 19589398]
177. Taylor CT. Interdependent roles for hypoxia inducible factor and nuclear factor-kappaB in hypoxic inflammation. J Physiol. 2008; 586(Pt 17):4055–9. [PubMed: 18599532]
178. Metelitsina TI, Grunwald JE, DuPont JC, Ying GS, Brucker AJ, Dunaief JL. Foveolar choroidal circulation and choroidal neovascularization in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2008; 49(1):358–63. [PubMed: 18172113]
179. Grunwald JE, Metelitsina TI, Dupont JC, Ying GS, Maguire MG. Reduced foveolar choroidal blood flow in eyes with increasing AMD severity. Invest Ophthalmol Vis Sci. 2005; 46(3):1033–8. [PubMed: 15728562]
180. Schlingemann RO. Role of growth factors and the wound healing response in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2004; 242(1):91–101. [PubMed: 14685874]
181. Yuan G, Nanduri J, Khan S, Semenza GL, Prabhakar NR. Induction of HIF-1alpha expression by intermittent hypoxia: involvement of NADPH oxidase, Ca2+ signaling, prolyl hydroxylases, and mTOR. J Cell Physiol. 2008; 217(3):674–85. [PubMed: 18651560]
182. Frede S, Berchner-Pfannschmidt U, Fandrey J. Regulation of hypoxia-inducible factors during inflammation. Methods Enzymol. 2007; 435:405–19. [PubMed: 17998066]
183. Sheridan CM, Pate S, Hiscott P, Wong D, Pattwell DM, Kent D. Expression of hypoxia-inducible factor-1alpha and -2alpha in human choroidal neovascular membranes. Graefes Arch Clin Exp Ophthalmol. 2009; 247(10):1361–7. [PubMed: 19590888]
184. Inoue Y, Yanagi Y, Matsuura K, Takahashi H, Tamaki Y, Araie M. Expression of hypoxia-inducible factor 1alpha and 2alpha in choroidal neovascular membranes associated with age-related macular degeneration. Br J Ophthalmol. 2007; 91(12):1720–1. [PubMed: 18024825]

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

185. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006; 90(3):262–7. [PubMed: 16488940]

186. Liu Y, Allingham RR. Molecular genetics in glaucoma. Exp Eye Res. 2011; 93(4):331–9. [PubMed: 21871452]

187. Quigley HA. Glaucoma. Lancet. 2011; 377(9774):1367–77. [PubMed: 21453963]

188. Flammer J, Orgul S, Costa VP, et al. The impact of ocular blood flow in glaucoma. Prog Retin Eye Res. 2002; 21(4):359–93. [PubMed: 12150988]

189. Osborne NN, Melena J, Chidlow G, Wood JP. A hypothesis to explain ganglion cell death caused by vascular insults at the optic nerve head: possible implication for the treatment of glaucoma. Br J Ophthalmol. 2001; 85(10):1252–9. [PubMed: 11567974]

190. Tezel G, Wax MB. Hypoxia-inducible factor 1alpha in the glaucomatous retina and optic nerve head. Arch Ophthalmol. 2004; 122(9):1348–56. [PubMed: 15364715]

191. Ng EW, Adamis AP. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol. 2005; 40(3):352–68. [PubMed: 15947805]

192. Lashkari K, Hirose T, Yazdany J, McMeel JW, Kazlauskas A, Rahimi N. Vascular endothelial growth factor and hepatocyte growth factor levels are differentially elevated in patients with advanced retinopathy of prematurity. Am J Pathol. 2000; 156(4):1337–44. [PubMed: 10751359]

193. Tripathi RC, Li J, Tripathi BJ, Chalam KV, Adamis AP. Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. Ophthalmology. 1998; 105(2):232–7. [PubMed: 9479280]

194. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994; 331(22): 1480–7. [PubMed: 7526212]

195. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004; 25(4):581–611. [PubMed: 15294883]

196. Famiglietti EV, Stopa EG, McGookin ED, Song P, LeBlanc V, Streeten BW. Immunocytochemical localization of vascular endothelial growth factor in neurons and glial cells of human retina. Brain Res. 2003; 969(1-2):195–204. [PubMed: 12676380]

197. Takagi H, King GL, Aiello LP. Identification and characterization of vascular endothelial growth factor receptor (Flt) in bovine retinal pericytes. Diabetes. 1996; 45(8):1016–23. [PubMed: 8690146]

198. Aiello LP, Northrup JM, Keyt BA, Takagi H, Iwamoto MA. Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol. 1995; 113(12):1538–44. [PubMed: 7487623]

199. Thieme H, Aiello LP, Takagi H, Ferrara N, King GL. Comparative analysis of vascular endothelial growth factor receptors on retinal and aortic vascular endothelial cells. Diabetes. 1995; 44(1):98–103. [PubMed: 7529203]

200. Kimoto K, Kubota T. Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability. J Ophthalmol. 2012; 2012:852183. [PubMed: 22132316]

201. Tolentino M. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol. 2011; 56(2):95–113. [PubMed: 21335144]

202. Campa C, Harding SP. Anti-VEGF compounds in the treatment of neovascular age related macular degeneration. Curr Drug Targets. 2011; 12(2):173–81. [PubMed: 20887245]

203. Pieramici DJ, Rabena MD. Anti-VEGF therapy: comparison of current and future agents. Eye. 2008; 22(10):1330–6. [PubMed: 18497829]

204. Quaggin SE. Turning a blind eye to anti-VEGF toxicities. J Clin Invest. 2012; 122(11):3849–51. [PubMed: 23093785]

205. Kurihara T, Westenskow PD, Bravo S, Aguilar E, Friedlander M. Targeted deletion of Vegfa in adult mice induces vision loss. J Clin Invest. 2012; 122(11):4213–7. [PubMed: 23093773]

206. Terzuoli E, Puppo M, Rapisarda A, et al. Aminoflavone, a ligand of the aryl hydrocarbon receptor, inhibits HIF-1alpha expression in an AhR-independent fashion. Cancer Res. 2010; 70(17):6837–48. [PubMed: 20736373]

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

207. Greenberger LM, Horak ID, Filpula D, et al. A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth. Mol Cancer Ther. 2008; 7(11):3598–608. [PubMed: 18974394]
208. Lin M, Hu Y, Chen Y, et al. Impacts of hypoxia-inducible factor-1 knockout in the retinal pigment epithelium on choroidal neovascularization. Invest Ophthalmol Vis Sci. 2012; 53(10): 6197–206. [PubMed: 22915031]
209. Zhang H, Qian DZ, Tan YS, et al. Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc Natl Acad Sci USA. 2008; 105(50):19579–86. [PubMed: 19020076]
210. Koh MY, Spivak-Kroizman T, Venturini S, Welsh S, Williams RR, Kirkpatrick DL, et al. Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha. Mol Cancer Ther. 2008; 7(1):90–100. [PubMed: 18202012]
211. Rapisarda A, Uranchimeg B, Scudiero DA, et al. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res. 2002; 62(15):4316–24. [PubMed: 12154035]
212. Pore N, Jiang Z, Gupta A, Cerniglia G, Kao GD, Maity A. EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. Cancer Res. 2006; 66(6):3197–204. [PubMed: 16540671]
213. Buchler P, Reber HA, Buchler MW, Friess H, Lavey RS, Hines OJ. Antiangiogenic activity of genistein in pancreatic carcinoma cells is mediated by the inhibition of hypoxia-inducible factor-1 and the down-regulation of VEGF gene expression. Cancer. 2004; 100(1):201–10. [PubMed: 14692041]
214. Jiang BH, Jiang G, Zheng JZ, Lu Z, Hunter T, Vogt PK. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ. 2001; 12(7):363–9. [PubMed: 11457733]
215. Pore N, Gupta AK, Cerniglia GJ, et al. Nelfinavir down-regulates hypoxia-inducible factor 1alpha and VEGF expression and increases tumor oxygenation: implications for radiotherapy. Cancer Res. 2006; 66(18):9252–9. [PubMed: 16982770]
216. Zhang Q, Tang X, Lu QY, Zhang ZF, Brown J, Le AD. Resveratrol inhibits hypoxia-induced accumulation of hypoxia-inducible factor-1alpha and VEGF expression in human tongue squamous cell carcinoma and hepatoma cells. Mol Cancer Ther. 2005; 4(10):1465–74. [PubMed: 16227395]
217. Mabuchi S, Altomare DA, Cheung M, et al. RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin Cancer Res. 2007; 13(14):4261–70. [PubMed: 17634556]
218. Wang W, Jia WD, Xu GL, et al. Antitumoral activity of rapamycin mediated through inhibition of HIF-1alpha and VEGF in hepatocellular carcinoma. Dig Dis Sci. 2009; 54(10):2128–36. [PubMed: 19052864]
219. Garcia-Maceira P, Mateo J. Silibinin inhibits hypoxia-inducible factor-1alpha and mTOR/p70S6K/4E-BP1 signalling pathway in human cervical and hepatoma cancer cells: implications for anticancer therapy. Oncogene. 2009; 28(3):313–24. [PubMed: 18978810]
220. Wan X, Shen N, Mendoza A, Khanna C, Helman LJ. CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling. Neoplasia. 2006; 8(5):394–401. [PubMed: 16790088]
221. Kumar SM, Yu H, Edwards R, et al. Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma. Cancer Res. 2007; 67(7):3177–84. [PubMed: 17409425]
222. Fang J, Zhou Q, Liu LZ, et al. Apigenin inhibits tumor angiogenesis through decreasing HIF-1alpha and VEGF expression. Carcinogenesis. 2007; 28(4):858–64. [PubMed: 17071632]
223. Kim WY, Oh SH, Woo JK, Hong WK, Lee HY. Targeting heat shock protein 90 overrides the resistance of lung cancer cells by blocking radiation-induced stabilization of hypoxia-inducible factor-1alpha. Cancer Res. 2009; 69(4):1624–32. [PubMed: 19176399]
224. Alqawi O, Moghaddas M, Singh G. Effects of geldanamycin on HIF-1alpha mediated angiogenesis and invasion in prostate cancer cells. Prostate Cancer Prostatic Dis. 2006; 9(2):126–35. [PubMed: 16432534]

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

225. Mie Lee Y, Kim SH, Kim HS, et al. Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, *via* suppression of HIF-1alpha activity. Biochem Biophys Res Commun. 2003; 300(1):241–6. [PubMed: 12480550]
226. Shankar S, Davis R, Singh KP, Kurzrock R, Ross DD, Srivastava RK. Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice. Mol Cancer Ther. 2009; 8(6):1596–605. [PubMed: 19509267]
227. Yang QC, Zeng BF, Shi ZM, et al. Inhibition of hypoxia-induced angiogenesis by trichostatin A *via* suppression of HIF-1a activity in human osteosarcoma. J Exp Clin Cancer Res. 2006; 25(4): 593–9. [PubMed: 17310851]
228. Newcomb EW, Ali MA, Schnee T, et al. Flavopiridol downregulates hypoxia-mediated hypoxia-inducible factor-1alpha expression in human glioma cells by a proteasome-independent pathway: implications for *in vivo* therapy. Neuro Oncol. 2005; 7(3):225–35. [PubMed: 16053697]
229. Duyndam MC, van Berkel MP, Dorsman JC, Rockx DA, Pinedo HM, Boven E. Cisplatin and doxorubicin repress Vascular Endothelial Growth Factor expression and differentially down-regulate Hypoxia-inducible Factor I activity in human ovarian cancer cells. Biochem Pharmacol. 2007; 74(2):191–201. [PubMed: 17498666]
230. Kong D, Park EJ, Stephen AG, et al. Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. Cancer Res. 2005; 65(19):9047–55. [PubMed: 16204079]
231. Olenyuk BZ, Zhang GJ, Klco JM, Nickols NG, Kaelin WG Jr, Dervan PB. Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist. Proc Natl Acad Sci USA. 2004; 101(48):16768–73. [PubMed: 15556999]
232. Mabjeesh NJ, Escuin D, LaVallee TM, et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer cell. 2003; 3(4):363–75. [PubMed: 12726862]
233. Bae MK, Kim SH, Jeong JW, et al. Curcumin inhibits hypoxia-induced angiogenesis *via* down-regulation of HIF-1. Oncol Rep. 2006; 15(6):1557–62. [PubMed: 16685395]
234. Maeda M, Hasebe Y, Egawa K, Shibanuma M, Nose K. Inhibition of angiogenesis and HIF-1alpha activity by antimycin A1. Biol Pharm Bull. 2006; 29(7):1344–8. [PubMed: 16819166]
235. Shin DH, Chun YS, Lee DS, Huang LE, Park JW. Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1. Blood. 2008; 111(6):3131–6. [PubMed: 18174379]
236. Kung AL, Zabludoff SD, France DS, et al. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer cell. 2004; 6(1):33–43. [PubMed: 15261140]
237. Yasui H, Ogura A, Asanuma T, et al. Inhibition of HIF-1alpha by the anticancer drug TAS106 enhances X-ray-induced apoptosis *in vitro* and *in vivo*. Br J Cancer. 2008; 99(9):1442–52. [PubMed: 18854835]
238. Zhao Q, Du J, Gu H, et al. Effects of YC-1 on hypoxia-inducible factor 1-driven transcription activity, cell proliferative vitality, and apoptosis in hypoxic human pancreatic cancer cells. Pancreas. 2007; 34(2):242–7. [PubMed: 17312464]
239. Welsh SJ, Williams RR, Birmingham A, Newman DJ, Kirkpatrick DL, Powis G. The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation. Mol Cancer Ther. 2003; 2(3): 235–43. [PubMed: 12657718]
240. Young RM, Wang SJ, Gordan JD, Ji X, Liebhaber SA, Simon MC. Hypoxia-mediated selective mRNA translation by an internal ribosome entry site-independent mechanism. J Biol Chem. 2008; 283(24):16309–19. [PubMed: 18430730]
241. Chen P, Yin H, Wang Y, Xie L. Inhibition of VEGF expression and corneal neovascularization by shRNA targeting HIF-1alpha in a mouse model of closed eye contact lens wear. Molecular vision. 2012; 18:864–73. [PubMed: 22511848]

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

242. Zhang H, Qian DZ, Tan YS, et al. Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc Natl Acad Sci USA. 2008; 105(50):19579–86. [PubMed: 19020076]

243. Yoshida T, Zhang H, Iwase T, Shen J, Semenza GL, Campochiaro PA. Digoxin inhibits retinal ischemia-induced HIF-1alpha expression and ocular neovascularization. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2010; 24(6): 1759–67. [PubMed: 20065104]

244. Wang B, Zou Y, Li H, Yan H, Pan JS, Yuan ZL. Genistein inhibited retinal neovascularization and expression of vascular endothelial growth factor and hypoxia inducible factor 1alpha in a mouse model of oxygen-induced retinopathy. J Ocul Pharmacol Ther. 2005; 21(2):107–13. [PubMed: 15857276]

245. Neckers L. Heat shock protein 90: the cancer chaperone. J Biosci. 2007; 32(3):517–30. [PubMed: 17536171]

246. Isaacs JS, Jung YJ, Mimnaugh EG, Martinez A, Cuttitta F, Neckers LM. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J Biol Chem. 2002; 277(33):29936–44. [PubMed: 12052835]

247. Kim WY, Oh SH, Woo JK, Hong WK, Lee HY. Targeting heat shock protein 90 overrides the resistance of lung cancer cells by blocking radiation-induced stabilization of hypoxia-inducible factor-1alpha. Cancer research. 2009; 69(4):1624–32. [PubMed: 19176399]

248. Kim JH, Yu YS, Shin JY, Lee HY, Kim KW. Deguelin inhibits retinal neovascularization by down-regulation of HIF-1alpha in oxygen-induced retinopathy. Journal of cellular and molecular medicine. 2008; 12(6A):2407–15. [PubMed: 18208562]

249. Lee K, Qian DZ, Rey S, Wei H, Liu JO, Semenza GL. Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells. Proc Natl Acad Sci USA. 2009; 106(7):2353–8. [PubMed: 19168635]

250. Kong D, Park EJ, Stephen AG, et al. Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. Cancer Res. 2005; 65(19):9047–55. [PubMed: 16204079]

Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript



Fig. (1).

Structure of HIF-1 subunits depicting various domains. (NLS - nuclear localizing signal; bHLH - basic helix-loop-helix; PAS -PER-ARNT-SIM; ODD - oxygen-dependent degradation; TAD - transactivating domain; ID - inhibitory domain).

Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript



Fig. (2).

Schematic representation of oxygen dependent HIF-1 stability and transactivation. (PHD - prolyl hydroxylase; FIH - factor inhibiting HIF; ARD - acetyltransferase; CBP - CREB binding protein; VHL - von Hippel-Lindau protein; HRE - hypoxia response element).

Author Manuscript Author Manuscript Author Manuscript Author Manuscript



Fig. (3).

Schematic representation of angiogenic regulation by HIF-1. (VEGF - vascular endothelial cell growth factor; PGF - placental growth factor; PDGF-B - platelet derived growth factor-B; SDF-1 - stromal derived growth factor-1; VEGFR1 - VEGF receptor 1; MMPs -matrix metalloproteinases; PAI-1 - plasminogen activator inhibitor-1).

Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript



Fig. (4).

A) Stages of diabetic retinopathy (DR). B) Development of retinopathy of prematurity (ROP). Reproduced with permission from reference [152]. C) Schematic representation of dry and wet age-related macular degeneration (AMD). Reproduced with permission from reference [176].

Author Manuscript Author Manuscript Author Manuscript Author Manuscript



Fig. (5).

Estimation of retinal neovascularization in (A) control and (B) deguelin treated oxygen-induced retinopathy (OIR) mouse model. Reproduced with permission from reference [248].

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

Table 1

Target Genes of HIF-1 Pathway

Function	Oxygen Regulated Gene	Reference
Angiogenesis	Endocrine gland derived VEGF (EG-VEGF)	[77]
	Transforming growth factor-β3 (TGF- β3)	[78]
	Vascular endothelial growth factor (VEGF)	[79]
	VEGF receptor (VEGFR1/Flt-1)	[80]
Apoptosis	Nip3	[81]
Cell proliferation and survival	Insulin-like growth factor (IGF) 2	[82]
	IGF-binding protein (IGFBP) -1	[83]
	IGFBP-2	[82]
	IGFBP-3	[82]
	Transforming growth factor- α (TGF-α)	[84]
Dedifferentiation	Inhibitor of differentiation protein-2 (ID2)	[85]
Drug resistance	Breast cancer resistance protein (BCRP)	[86]
	P-glycoprotein (P-gp/MDR1)	[87]
Energy metabolism	Leptin	[88]
Erythropoiesis	Erythropoietin (EPO)	[5]
Genetic instability	MutSalpha (MSH2 and MSH6 complex)	[89]
Glucose metabolism	Aldolase-A	[90]
	Aldolase-C	[90]
	Enolase-1	[90]
	Glucose transporter-1 (GLUT-1)	[91]
	GLUT-3	[92]
	Hexokinase-1	[90]
	Hexokinase-2	[90]
	Lactate dehydrogenase A (LDHA)	[93]
	Phosphofructokinase L (PFKL)	[93]
	Phosphoglycerate kinase 1 (PGK1)	[93]
Histone modifiers	JMJD2B	[94]
Iron metabolism	Ceruloplasmin	[95]
	Transferrin	[96]
	Transferrin receptor	[97]
Matrix metabolism	Collagen prolyl hydroxylase	[98]
	Matrix metalloproteinases (MMPs)	[99]
	Plasminogen activator inhibitor -1 (PAI-1)	[100]
Migration/Invasion	$\alpha_v\beta_3$ integrin	[101]
	Chemokine receptor (CXCR4)	[102]
Nucleotide metabolism	Adenylate kinase-3	[91]

Function	Oxygen Regulated Gene	Reference
pH regulation	Carbonic anhydrase-9	[103]
Transcriptional factor	ETS-1	[104]
Vascular tone	α_{1B}-Adrenergic receptor	[105]
	Adrenomedulin (ADM)	[106]
	Endothelin-1 (ET1)	[107]
	Heme oxygenase-1 (HO-1)	[108]
	Inducible nitric oxide synthase (iNOS)	[109]

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

Table 2

Inhibitors of HIF-1 Pathway

Target Pathway / Mechanism of Action	Small Molecules	Reference
HIF-1α mRNA expression		
Transcription	Aminoflavone	[206]
	EZN-2968	[207]
	RNA interference	[208]
HIF-1α protein expression		
Translation	Digoxin	[209]
	PX-478	[210]
	Topotecan	[211]
Receptor tyrosine kinases	Erotinib	[212]
	Gefitinib	[212]
	Genistein	[213]
PI3K-AKT pathway	LY294002	[214]
	Nelfinavir	[215]
	Wortmannin	[214]
ERK-AKT pathway	Resveratrol	[216]
mTOR pathway	Everolimus	[217]
	Rapamycin	[218]
	Silibinin	[219]
	Temsirolimus	[220]
Ras-MAPK pathway	PD98059	[64]
	Sorafenib	[221]
HIF-1α protein degradation		
Hsp90 inhibitor	Apigenin	[222]
	Deguelin	[223]
	Geldanamycin	[224]
HDAC inhibitor	FK228	[225]
	SAHA	[226]
	Trichostatin A	[227]
Others		
Cyclin-dependent kinase	Flavopiridol	[228]
DNA binding	Cisplatin	[229]
	Doxorubicin	[229]
	Echinomycin	[230]
	Pyrrole - imidazole polyamide	[231]
Microtubules	2-methoxyestradiol (2ME2)	[232]
Others		
	Curcumin	[233]

Target Pathway / Mechanism of Action	Small Molecules	Reference
Mitochondria	Antimycin A1	[234]
p300 interaction	Bortezomib	[235]
	Chetomin	[236]
RNA polymerase	ECyd	[237]
Soluble guanylyl cyclase stimulator	YC-1	[238]
Thioredoxin redox system	Pleurotin	[239]

(PI3K - Phosphatidylinositide 3-Kinases; AKT - Protein Kinase B; ERK - Extracellular Signal-Regulated Kinases; mTOR - Mammalian Target of Rapamycin; Hsp - Heat Shock Protein; HDAC - Histone Deacetylase).

Author Manuscript Author Manuscript Author Manuscript Author Manuscript